Corporate

Follows Favorable Multi-District Litigation Court Causation Ruling and the Company’s Successful Strategy to Defend Each Case Efficient Conclusion to the Talc Litigation that Eliminates Expense Associated with Litigating Remaining 76,000 Ovarian Talc Claims

• Investment includes new advanced manufacturing and packaging technologies and a new state-of-the-art distribution facility to scale the Company’s U.S. Vision operations, enhance supply chain resilience, and meet the needs of more than 40 million patients
• Investment is part of the Company’s ongoing $55 billion commitment to U.S. manufacturing, research and development, and technology through early 2029
• Building on more than 40 years of leadership in Florida, the investment supports 3,500 Jacksonville employees and strengthens Johnson & Johnson’s $6 billion annual economic impact across the state

Advances Company’s industry-leading portfolio in mental health with addition of CAPLYTA® (lumateperone), the first and only U.S. FDA-approved treatment for bipolar I and II depression as an adjunctive therapy and monotherapy; also approved for the treatment of schizophrenia in adults sNDA submitted to U.S. FDA for CAPLYTA® as adjunctive treatment for major depressive disorder; if approved, has potential to become a new standard of care for most common depressive disorders Addition of CAPLYTA® strengthens J&J’s robust lineup of therapies with $5 billion+ potential in peak year salesi, further solidifying sales growth above analyst expectations now through the remainder of the decade Acquisition also includes promising clinical-stage pipeline with best-in-class potential in generalized anxiety disorder and Alzheimer’s disease-related psychosis and agitation

Company has prevailed in 16 of 17 ovarian cases tried in the last 11 years Company will reverse approximately $7 billion from amounts previously reserved for the bankruptcy resolution

Acquisition includes CAPLYTA® (lumateperone), the first and only U.S. FDA-approved treatment for bipolar I and II depression as an adjunctive and monotherapy; also approved for the treatment of schizophrenia in adults sNDA submitted to U.S. FDA for CAPLYTA® as adjunctive treatment for major depressive disorder; if approved, CAPLYTA® has potential to become a standard of care for most common depressive disorders CAPLYTA® adds to Johnson & Johnson’s robust lineup of therapies with $5 billion+ potential in peak year salesi and further solidifies sales growth above analyst expectations now through the remainder of the decade Promising clinical-stage pipeline with best-in-disease potential in generalized anxiety disorder and Alzheimer’s disease-related psychosis and agitation